EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BCL11B expression in hepatocellular carcinoma relates to chemosensitivity and clinical prognosis

Hiroyuki Abe, Kenya Kamimura iD, Shujiro Okuda, Yu Watanabe, Jun Inoue, Yutaka Aoyagi, Toshifumi Wakai, Ryo Kominami, Shuji Terai

Cancer Medicine · 2023

DOI: 10.1002/cam4.6167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Hiroyuki Abe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Niigata, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction B‐cell lymphoma/leukemia 11B (BCL11B) is a subunit of SWI/SNF chromatin remodeling complexes and functions in cell cycle regulation and apoptosis upon DNA replication stress and damages via transcription. Many malignancies were reported to exhibit changes in BCL11B gene expression; however, no study has focused on the relationship between BCL11B and hepatocellular carcinoma, which potentially exhibits DNA replication stress and damages upon its oncogenesis. Thus, in this study, we examined the molecular characterization of BCL11B expression in hepatocellular carcinoma. Methods and Results The cumulative progression‐free survival and overall survival were significantly longer in the clinical cases of BCL11B‐negative hepatocellular carcinoma than BCL11B‐positve cases. Microarray and real‐time PCR analyses in hepatocellular carcinoma cell lines indicated a correlation between BCL11B and GATA6, a gene reported to be correlated with oncogenic activities and resistance to anthracycline, which is often used for hepatocellular carcinoma chemotherapy. Consequently, BCL11B‐overexpressing cell lines exhibited resistance to anthracycline in cell growth assays and the resistance has been evidenced by the increased expression of BCL‐xL in cell lines. The results were supported by the analyses of human HCC samples showing the correlation between BCL11B and GATA6 expressions. Discussions and Conclusion Our results indicated that overexpression of BCL11B amplifies GATA6 expression in hepatocellular carcinoma in vitro and in vivo that leads to anti‐apoptotic signal activation, and induces resistance to chemotherapy, which influenced the postoperative prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansRepressor ProteinsTumor Suppressor ProteinsTranscription FactorsPrognosisAnthracyclinesApoptosisGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

BCL11BGATA6drug sensitivityhepatocellular carcinomaprognosis

Substanzen

Repressor ProteinsTumor Suppressor ProteinsTranscription FactorsAnthracyclinesBCL11B protein, human

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Niigata, Japan.
  • Department of General Medicine, Niigata University School of Medicine, Niigata, Niigata, Japan.
  • Division of Bioinformatics, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Niigata, Japan.
  • Department of Agricultural Chemistry, Faculty of Applied Biosciences, Tokyo University of Agriculture, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Niigata Medical Center, Niigata, Niigata, Japan.
  • Division of Digestive and General Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Niigata, Japan.

ORCID-Profile: Kenya Kamimura

Förderung

  • Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care

Zitieren

APA

Abe, H., Kamimura, K., Okuda, S., Watanabe, Y., Inoue, J., Aoyagi, Y., Wakai, T., Kominami, R., & Terai, S. (2023). BCL11B expression in hepatocellular carcinoma relates to chemosensitivity and clinical prognosis. Cancer Medicine. https://doi.org/10.1002/cam4.6167

Vancouver

Abe H, Kamimura K, Okuda S, Watanabe Y, Inoue J, Aoyagi Y, et al. BCL11B expression in hepatocellular carcinoma relates to chemosensitivity and clinical prognosis. Cancer Medicine. 2023. doi:10.1002/cam4.6167

BibTeX
@article{Abe2023,
  author = {Abe, Hiroyuki and Kamimura, Kenya and Okuda, Shujiro and Watanabe, Yu and Inoue, Jun and Aoyagi, Yutaka and Wakai, Toshifumi and Kominami, Ryo and Terai, Shuji},
  title = {BCL11B expression in hepatocellular carcinoma relates to chemosensitivity and clinical prognosis},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6167}
}
Kostenlos starten →